已发表的部分文献: 标题:CREB trans-activation of disruptor of telomeric silencing-1 mediates forskolin inhibition of CTGF transcription in mesangial cells.作者:Yu Z, Kong Q, Kone BC;杂志名称:Am J Physiol Renal Physiol 标题:Synergistic effect of retinoic acid and cytokines on the regulation of glial fibrillary acidic protein expression.作者:Herrera F, Chen Q, Schubert D;杂志名称:J Biol Chem 标题:Up-regulation of Hepatic VLDLR via PPARα Is Required for the Triglyceride-Lowering Effect of Fenofibrate.作者:Gao Y The Univer, Shen W, Zhang Q, Hu Y, Chen Y;杂志名称:J Lipid Res 标题:Inhibition of red blood cell development by arsenic-induced disruption of GATA-1.作者:Zhou X, Medina S, Bolt AM, Zhang H, Wan G, Xu H, Lauer FT, Wang SC, Burchiel SW, Liu KJ;杂志名称:Sci Rep 标题:Uranium directly interacts with the DNA repair protein poly (ADP-ribose) polymerase 1.作者:Zhou X, Xue B, Medina S, Burchiel SW, Liu KJ;杂志名称:Toxicol Appl Pharmacol Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。